Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.41 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11073965 | 0.81 | CYP19A1 (0.43) | MEN1KMT2APOLBALDH1A1MMP2 | |
| SCHEMBL24670440 | 0.78 | CA1 (0.44) | CA1CA2MEN1KMT2AALDH1A1 | |
| SCHEMBL1096992 | 0.78 | PARL (0.47) | CA1CA2MEN1KMT2APKM | |
| SCHEMBL24668714 | 0.78 | TP53 (0.38) | KMT2APKMSMN1; SMN2 | |
| SCHEMBL2386706 | 0.74 | RAPGEF4 (0.45) | CA1CA2MEN1KMT2AHTT | |
| SCHEMBL4993025 | 0.73 | GRM4 (0.51) | CA1CA2MEN1KMT2APKM | |
| SCHEMBL29509 | 0.72 | ALDH1A1 (0.45) | CA1CA2KMT2APKMPOLB | |
| SCHEMBL4881482 | 0.71 | MAPT (0.47) | CA1CA2MEN1KMT2APKM | |
| SCHEMBL3316587 | 0.71 | CA1 (0.55) | CA1CA2MEN1KMT2APKM | |
| SCHEMBL24254271 | 0.71 | KMT2A (0.49) | MEN1KMT2APKMPOLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114805229-B | Preparation of 1,2, 4-triazole | 兰州大学 | 2023-04-25 | — | — | CN | claimed |
| CN-114805229-A | Preparation of 1,2, 4-triazoles | 兰州大学 | 2022-07-29 | — | — | CN | claimed |
| WO-2008034644-A2 | PROCESS FOR MAKING ANASTROZOLE | SYNTHON B.V. (NL) | 2008-03-27 | — | — | WO | claimed |
| US-20080076933-A1 | PROCESS FOR MAKING ANASTROZOLE | SYNTHON BV (NL) | 2008-03-27 | — | — | US | claimed |
| CN-113923988-B | Substituted arylmethyl ureas and heteroarylmethyl ureas, analogs thereof, and methods of using the same | 爱彼特生物制药公司 | 2024-12-13 | — | — | CN | disclosed |
| EP-3893645-B1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2024-04-17 | — | — | EP | disclosed |
| CN-114805229-B | Preparation of 1,2, 4-triazole | 兰州大学 | 2023-04-25 | — | — | CN | disclosed |
| CN-114805229-B | Preparation of 1,2, 4-triazole | 兰州大学 | 2023-04-25 | — | — | CN | disclosed |
| US-20230045421-A1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-02-09 | — | — | US | disclosed |
| US-20230045421-A1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-02-09 | — | — | US | disclosed |
| CN-114805229-A | Preparation of 1,2, 4-triazoles | 兰州大学 | 2022-07-29 | — | — | CN | disclosed |
| CN-114805229-A | Preparation of 1,2, 4-triazoles | 兰州大学 | 2022-07-29 | — | — | CN | disclosed |
| WO-2008034644-A2 | PROCESS FOR MAKING ANASTROZOLE | SYNTHON B.V. (NL) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008034644-A2 | PROCESS FOR MAKING ANASTROZOLE | SYNTHON B.V. (NL) | 2008-03-27 | — | — | WO | disclosed |
| US-20060155136-A1 | Optically active halohydrin derivative and process for producing optically active epoxy alcohol derivative from the same | KANEKA CORPORATION (JP) | 2006-07-13 | — | — | US | disclosed |
| EP-1647551-A1 | OPTICALLY ACTIVE HALOHYDRIN DERIVATIVE AND PROCESS FOR PRODUCING OPTICALLY ACTIVE EPOXY ALCOHOL DERIVATIVE FROM THE SAME | KANEKA CORPORATION (JP) | 2006-04-19 | — | — | EP | disclosed |
| EP-0613890-A1 | Novel triazole compound, process for preparing the same and antifungal agent containing the same | NIHON NOHYAKU CO., LTD. (JP) | 1994-09-07 | — | — | EP | disclosed |
| EP-0009998-B1 | PEROXYGEN CONTAINING COMPOSITIONS AND BLEACHING PROCESS | FMC Corporation (US) | 1984-03-14 | — | — | EP | disclosed |
| US-4230591-A | Peroxygen bleaching and compositions therefor | FMC CORPORATION (US) | 1980-10-28 | — | — | US | disclosed |
| US-4207070-A | Peroxygen bleaching and compositions therefor | FMC CORPORATION (US) | 1980-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060155136-A1 | Optically active halohydrin derivative and process for producing optically active epoxy alcohol derivative from the same | TALDO1, CYP51A1, ERG28 | CA1 1130/4885CA2 752/4885MEN1 3817/4885 |
| US-20080076933-A1 | PROCESS FOR MAKING ANASTROZOLE | CYP19A1, CYP3A4, CYP2C19 | CA1 3496/4885CA2 4294/4885MEN1 1523/4885 |
| US-20230045421-A1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | HAVCR2, HMBS, AHCY | CA1 4853/4885CA2 4816/4885MEN1 1955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.